Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Sicurezza ed efficacia del ritmo dell'area del ramo del pacchetto sinistro rispetto alla terapia di risincronizzazione cardiaca convenzionale nell'insufficienza cardiaca (SYNCHRONICITY)

2 novembre 2026 aggiornato da: Boston Scientific Corporation

This study will compare two different methods to pace the heart to treat heart failure including:

  1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).
  2. The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

850

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Alabama
      • Huntsville, Alabama, Stati Uniti, 35801
        • Reclutamento
        • Heart Center Research, LLC
        • Contatto:
          • John Jennings, Dr.
        • Investigatore principale:
          • John Jennings, Dr.
      • Mobile, Alabama, Stati Uniti, 36608
        • Reclutamento
        • Mobile Infirmary Medical Center
        • Contatto:
          • Ernest Matthew Quin, Dr.
        • Investigatore principale:
          • Ernest Matthew Quin, Dr.
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85054
        • Reclutamento
        • Mayo Clinic Phoenix
        • Contatto:
          • Mayank Sardana, MD
        • Investigatore principale:
          • Mayank Sardana, MD
    • Arkansas
      • Jonesboro, Arkansas, Stati Uniti, 72401
        • Reclutamento
        • Arrhythmia Research Group
        • Contatto:
          • Devi Nair, Dr.
        • Investigatore principale:
          • Devi Nair, Dr.
    • California
      • La Jolla, California, Stati Uniti, 92037
        • Reclutamento
        • Scripps Memorial Hospital
        • Contatto:
          • Nicolas Olson, MD
        • Investigatore principale:
          • Nicolas Olson, MD
      • Los Angeles, California, Stati Uniti, 90048
        • Reclutamento
        • Cedars Sinai Medical Center
        • Investigatore principale:
          • Ashkan Ehdaie, MD
        • Contatto:
          • Ashkan Ehdaie, MD
      • Oakland, California, Stati Uniti, 94609
        • Reclutamento
        • Alta Bates Summit Medical Center
        • Contatto:
          • Rajan Shah, Dr.
        • Investigatore principale:
          • Rajan Shah, Dr.
      • Santa Monica, California, Stati Uniti, 90404
        • Reclutamento
        • Pacific Heart Institute
        • Contatto:
          • Stephen Tang, MD
        • Investigatore principale:
          • Stephan Tang, MD
      • Torrance, California, Stati Uniti, 90505
        • Reclutamento
        • Torrance Medical Center
        • Investigatore principale:
          • Gene Kim, MD
        • Contatto:
          • Gene Kim, MD
      • Ventura, California, Stati Uniti, 93003
        • Reclutamento
        • Cardiology Associates Medical Group, Inc.
        • Contatto:
          • Jonathan Dukes, Dr.
        • Investigatore principale:
          • Jonathan Dukes, Dr.
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20010
        • Reclutamento
        • Washington Hospital Center
        • Contatto:
          • Cyrus Hadadi, MD
        • Investigatore principale:
          • Cyrus Hadadi, MD
    • Florida
      • Sarasota, Florida, Stati Uniti, 34239
        • Reclutamento
        • Sarasota Memorial Hospital
        • Contatto:
          • Antonio Moretta, Dr.
        • Investigatore principale:
          • Antonio Moretta, Dr.
      • Tampa, Florida, Stati Uniti, 33613
        • Reclutamento
        • AdventHealth Tampa
        • Investigatore principale:
          • Kenneth Yamamura, MD
        • Contatto:
          • Kenneth Yamamura, MD
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30309
        • Reclutamento
        • Piedmont Hospital
        • Contatto:
          • Kavita Krishnasamy, MD
        • Investigatore principale:
          • Kavita Krishnasamy, MD
      • Atlanta, Georgia, Stati Uniti, 30322
        • Reclutamento
        • Emory University Hospital
        • Contatto:
          • Anand Shah, MD
        • Investigatore principale:
          • Anand Shah, MD
    • Idaho
      • Meridian, Idaho, Stati Uniti, 83642
        • Reclutamento
        • St. Luke's Idaho Cardiology Associates
        • Contatto:
          • Justice Oranefo, MD
        • Investigatore principale:
          • Justice Oranefo, MD
    • Illinois
      • Hinsdale, Illinois, Stati Uniti, 60521
        • Reclutamento
        • University of Chicago
        • Contatto:
          • Shrinath Yeshwant, MD
        • Investigatore principale:
          • Shrinath Yeshwant, MD
      • Naperville, Illinois, Stati Uniti, 60540
        • Ritirato
        • Midwest Cardiovascular Institute
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46250
        • Reclutamento
        • Community Heart and Vascular Hospital
        • Contatto:
          • Krishna Malineni, MD
        • Investigatore principale:
          • Krishna Malineni, MD
    • Iowa
      • Iowa City, Iowa, Stati Uniti, 52242
        • Reclutamento
        • University of Iowa Hospitals and Clinics
        • Investigatore principale:
          • Paari Dominic, MD
        • Contatto:
          • Paari Dominic, MD
    • Kentucky
      • Louisville, Kentucky, Stati Uniti, 40207
        • Reclutamento
        • Baptist Hospital East Louisville
        • Investigatore principale:
          • Kevin Parrott, MD
        • Contatto:
          • Kevin Parrott, MD
    • Massachusetts
      • Fall River, Massachusetts, Stati Uniti, 02720
        • Reclutamento
        • Southcoast Physicians Group
        • Contatto:
          • Arnoldas Giedrimas, MD
        • Investigatore principale:
          • Arnoldas Giedrimas, MD
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Reclutamento
        • University of Michigan Hospitals
        • Investigatore principale:
          • Thomas Crawford, MD
        • Contatto:
          • Thomas Crawford, MD
      • Grand Rapids, Michigan, Stati Uniti, 49525
        • Reclutamento
        • Corewell Health
        • Contatto:
          • Jawad Wassim, MD
        • Investigatore principale:
          • Jawad Wassim, MD
    • Minnesota
      • Duluth, Minnesota, Stati Uniti, 55805
        • Ritirato
        • St. Mary's Duluth Clinic Regional Heart Center
      • Saint Cloud, Minnesota, Stati Uniti, 56303
        • Ritirato
        • Centracare Heart and Vascular Center
    • New Jersey
      • Morristown, New Jersey, Stati Uniti, 07932
        • Reclutamento
        • Morristown Medical Center
        • Contatto:
          • Michael Katz, MD
        • Investigatore principale:
          • Michael Katz, MD
    • New York
      • Albany, New York, Stati Uniti, 12211
        • Reclutamento
        • Capital Cardiology Associates
        • Contatto:
          • Rizwan Alimohammad, MD
        • Investigatore principale:
          • Rizwan Alimohammad, MD
      • Flushing, New York, Stati Uniti, 11355
        • Reclutamento
        • New York Hospital Queens
        • Contatto:
          • Seth Goldbarg, Dr.
        • Investigatore principale:
          • Seth Goldbarg, Dr.
      • New York, New York, Stati Uniti, 10021
        • Reclutamento
        • Weill Cornell Medical University
        • Contatto:
          • Jim Cheung, Dr.
        • Investigatore principale:
          • Jim Cheung, Dr.
      • New York, New York, Stati Uniti, 14621
        • Reclutamento
        • Rochester General Hospital
        • Contatto:
          • Dmitry Chuprun, MD
        • Investigatore principale:
          • Dmitry Chuprun, MD
      • Syracuse, New York, Stati Uniti, 13057
        • Reclutamento
        • SUNY-Upstate Medical University
        • Contatto:
          • Jorge Romero, MD
        • Investigatore principale:
          • Jorge Romero, MD
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28204
        • Reclutamento
        • Sanger Heart and Vascular Institute
        • Contatto:
          • Navid Nafissi, MD
        • Investigatore principale:
          • Navid Nafissi, MD
      • Durham, North Carolina, Stati Uniti, 27710
        • Reclutamento
        • Duke University Medical Center
        • Contatto:
          • Daniel Friedman, MD
        • Investigatore principale:
          • Daniel Friedman, MD
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43219
        • Reclutamento
        • Mount Carmel Health System
        • Contatto:
          • Kamel Addo, MD
        • Investigatore principale:
          • Kamel Addo, MD
      • Columbus, Ohio, Stati Uniti, 43214
        • Reclutamento
        • OhioHealth Research and Innovation Institute-Riverside Methodist Hospital
        • Contatto:
          • Anish Amin, MD
        • Investigatore principale:
          • Anish Amin, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Reclutamento
        • Penn Presbyterian Medical Center
        • Contatto:
          • John Bullinga, MD
        • Investigatore principale:
          • John Bullinga, MD
      • Wilkes-Barre, Pennsylvania, Stati Uniti, 18702
        • Reclutamento
        • Geisinger Wyoming Valley
        • Investigatore principale:
          • Pugazhendhi Vijayaraman, MD
        • Contatto:
          • Pugazhendhi Vijayaraman, MD
    • South Dakota
      • Sioux Falls, South Dakota, Stati Uniti, 57108
        • Reclutamento
        • Avera Heart Hospital of South Dakota
        • Contatto:
          • Christopher Stanton, Dr.
        • Investigatore principale:
          • Christopher Stanton, Dr.
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37205
        • Reclutamento
        • St.Thomas Health
        • Contatto:
          • Ricardo Lugo, MD
        • Investigatore principale:
          • Ricardo Lugo, MD
    • Texas
      • Plano, Texas, Stati Uniti, 75093
        • Reclutamento
        • Heart Hospital Baylor Plano
        • Contatto:
          • Mustafa Dohadwala, MD
        • Investigatore principale:
          • Mustafa Dohadwala, MD
      • Tyler, Texas, Stati Uniti, 75701
        • Reclutamento
        • Christus Trinity Mother Frances Health System
        • Contatto:
          • Stanislov Weiner, Dr.
        • Investigatore principale:
          • Stanislov Weiner, Dr.
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22908
        • Reclutamento
        • University of Virginia Medical Center
        • Investigatore principale:
          • Pamela Mason, MD
        • Contatto:
          • Pamela Mason, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law

  2. Patient meets a guideline-based indication for a de novo CRT-D device

  3. Primary prevention indication for ICD therapy

  4. Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)

  5. NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)* for at least 3 months

    *GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications

  6. Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment

  7. Patient is willing to participate in LATITUDE™ NXT remote patient monitoring

  8. Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)

  9. Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)

Exclusion Criteria:

  1. Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record
  2. Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and/or other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment
  3. Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment
  4. Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment
  5. Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)
  6. Prior or planned mechanical or bioprosthetic tricuspid valve replacement
  7. Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment
  8. Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment
  9. History of heart transplantation or left ventricular assist device (LVAD) implantation
  10. Less than 1 year of life expectancy at the time of enrollment
  11. Anticipated heart transplantation or LVAD implantation within 1 year of enrollment
  12. History of ventricular septal defect (VSD)
  13. Complex congenital heart disease
  14. Documented diagnosis of cardiac amyloidosis
  15. Known occlusion or other reason limiting central venous access for transvenous leads
  16. Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)
  17. Patient currently requiring dialysis
  18. Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
  19. Patient with contrast dye allergy or unwilling/able to undergo pre-treatment with steroids and/or diphenhydramine
  20. Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome
  21. Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: CRT Cohort

Participants will be randomized, implanted with a BSC CRT-D device using a Quadripolar lead, and device programmed to the respective cohort.

Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead.

Sperimentale: LBBA Cohort

Participants will be randomized, implanted with a BSC CRT-D using the INGEVITY+ pace/sense lead implanted in the LBBA, and device programmed to the respective cohort.

Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Lasso di tempo: Through study completion, up to maximum of 5 years

The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion.

Through study completion, up to maximum of 5 years
System-related complication-free rate
Lasso di tempo: 12 months

The primary safety endpoint is System-related complication-free rate of LBBAP at 12 months. This will be a single-arm analysis of the LBBAP group compared to a performance goal

12 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Win ratio composite assessment
Lasso di tempo: Through study completion, up to a maximum of 5 years

Win Ratio Ranking: 1) Death 2) Heart Transplant/LVAD 3) Number of Heart Failure (HF) events (includes in-patient, out-patient and HF re-admission 4) Number of VT/VF episodes requiring device therapy or external defibrillation/cardioversion (one episode per 24 hours 5) Change in MLHFQ (Minnesota Living with Heart Failure Questionnaire) quality of life

Through study completion, up to a maximum of 5 years
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Lasso di tempo: Through study completion, up to a maximum of 5 years

The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion.

Through study completion, up to a maximum of 5 years
System-related complication-free rate between randomized arms
Lasso di tempo: 12 months

System-related complication-free rate of LBBAP at 12 months. This will compare the two randomized arms.

12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

22 ottobre 2025

Completamento primario (Stimato)

1 novembre 2029

Completamento dello studio (Stimato)

1 novembre 2029

Date di iscrizione allo studio

Primo inviato

23 giugno 2025

Primo inviato che soddisfa i criteri di controllo qualità

7 luglio 2025

Primo Inserito (Effettivo)

17 luglio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • C2403

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .